CR20130106A - Nuevos moduladores de trpv3 - Google Patents

Nuevos moduladores de trpv3

Info

Publication number
CR20130106A
CR20130106A CR20130106A CR20130106A CR20130106A CR 20130106 A CR20130106 A CR 20130106A CR 20130106 A CR20130106 A CR 20130106A CR 20130106 A CR20130106 A CR 20130106A CR 20130106 A CR20130106 A CR 20130106A
Authority
CR
Costa Rica
Prior art keywords
new
trpv3 modulators
trpv3
modulators
compositions
Prior art date
Application number
CR20130106A
Other languages
English (en)
Inventor
Erol K Bayburt
Bruce Clapham
Phil B Cox
Jerome F Daanen
Arthur Gomtsyan
Michael E Kort
Philip R Kym
Eric A Voight
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Inc filed Critical Abbvie Inc
Publication of CR20130106A publication Critical patent/CR20130106A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
    • C07D213/46—Oxygen atoms
    • C07D213/50—Ketonic radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)

Abstract

Moduladores de TRPV3 de fórmula (I) (I),donde G1, X1, X2, X3, X4, X5, G2, Z1, Ra, Rb, u, y p son como se definen en la memoria descriptiva. Composiciones que comprenden dichos compuestos y métodos para tratar estados clínicos y trastornos usando dichos compuestos y composiciones.
CR20130106A 2010-08-10 2013-03-11 Nuevos moduladores de trpv3 CR20130106A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2010/001213 WO2012019315A1 (en) 2010-08-10 2010-08-10 Novel trpv3 modulators

Publications (1)

Publication Number Publication Date
CR20130106A true CR20130106A (es) 2013-07-19

Family

ID=45567252

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20130106A CR20130106A (es) 2010-08-10 2013-03-11 Nuevos moduladores de trpv3

Country Status (14)

Country Link
US (1) US9156788B2 (es)
EP (1) EP2603490A4 (es)
JP (1) JP2013538800A (es)
KR (1) KR20130097748A (es)
CN (1) CN103140476A (es)
AU (1) AU2010359001A1 (es)
BR (1) BR112013003121A2 (es)
CA (1) CA2807538A1 (es)
CR (1) CR20130106A (es)
MX (1) MX2013001612A (es)
PH (1) PH12013500275A1 (es)
RU (1) RU2013110324A (es)
SG (1) SG187811A1 (es)
WO (1) WO2012019315A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012019315A1 (en) 2010-08-10 2012-02-16 Abbott Laboratories Novel trpv3 modulators
WO2012100153A1 (en) * 2011-01-20 2012-07-26 Northeastern University Real-time pavement profile sensing system using air-coupled surface wave
WO2012129491A1 (en) 2011-03-24 2012-09-27 Abbott Laboratories Trpv3 modulators
CN104254522A (zh) * 2011-10-24 2014-12-31 艾伯维公司 作为trpv3调节剂的甲醇衍生物
MX2014004979A (es) 2011-10-24 2014-10-24 Abbvie Inc Derivados de metanol como moduladores de trpv3.
DE102013008118A1 (de) 2013-05-11 2014-11-13 Merck Patent Gmbh Arylchinazoline
CN109942459B (zh) * 2017-12-21 2022-06-24 南京理工大学 一种合成3-二氟甲基-3-丙烯腈类化合物的方法
CN110408590B (zh) * 2019-09-06 2022-10-25 遵义医学院附属医院 一种诱导人间充质干细胞向成骨细胞分化的方法与应用

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS54138547A (en) * 1978-04-14 1979-10-27 Takeda Chem Ind Ltd Beta-aminoketone derivative and its preparation
JPS60109539A (ja) * 1983-11-15 1985-06-15 Sumitomo Chem Co Ltd ベンジルアルコ−ル誘導体
JPS60230742A (ja) * 1984-04-28 1985-11-16 Shinko Electric Co Ltd ル−プ式デ−タ伝送方式における割込み信号伝送方法
JPS6471830A (en) * 1987-09-11 1989-03-16 Rikagaku Kenkyusho Monofluorocyclobutanes and production thereof
DE3914820A1 (de) * 1989-05-05 1990-11-08 Basf Ag Neue pyridinderivate und ihre verwendung als fungizide
DE4018260A1 (de) * 1990-06-07 1991-12-12 Basf Ag Derivate des (beta)-picolins und diese enthaltende pflanzenschutzmittel
DE4318916A1 (de) * 1993-06-07 1994-12-08 Bayer Ag Cyclobutylazole
GB9315808D0 (en) 1993-07-30 1993-09-15 Merck Sharp & Dohme Therapeutic agents
MY115155A (en) 1993-09-09 2003-04-30 Upjohn Co Substituted oxazine and thiazine oxazolidinone antimicrobials.
EP1019385B1 (en) 1995-09-15 2004-01-14 PHARMACIA & UPJOHN COMPANY Aminoaryl oxazolidinone n-oxides
US20030220234A1 (en) 1998-11-02 2003-11-27 Selvaraj Naicker Deuterated cyclosporine analogs and their use as immunodulating agents
CN1215715A (zh) * 1997-10-28 1999-05-05 兰州大学 立体选择性1,3－二醇合成方法
AU2720199A (en) * 1998-02-03 1999-08-23 Boehringer Ingelheim Pharma Kg Five-membered, benzo-condensed heterocycles used as antithrombotic agents
US6114532A (en) 1998-02-03 2000-09-05 Boehringer Ingelheim Pharma Kg Bicyclic heterocycles, the preparation thereof, and their use as pharmaceuticals
GB9918037D0 (en) 1999-07-30 1999-09-29 Biochemie Gmbh Organic compounds
AU9087301A (en) 2000-09-11 2002-03-26 Sepracor Inc Ligands for monoamine receptors and transporters, and methods of use thereof
JP2005500028A (ja) 2001-06-13 2005-01-06 ノバルティス　アクチエンゲゼルシャフト バニロイドレセプター関連核酸およびポリペプチド
ATE496620T1 (de) * 2002-04-11 2011-02-15 Merck Sharp & Dohme 1h-benzo(f)indazol-5-yl-derivate als selektive glucocorticoid-rezeptor-modulatoren
ZA200503654B (en) 2002-11-06 2006-09-27 Amgen Inc Fused heterocyclic compounds
EP1737850B1 (en) 2004-04-19 2007-10-03 Symed Labs Limited A novel process for the preparation of linezolid and related compounds
US7429661B2 (en) 2004-07-20 2008-09-30 Symed Labs Limited Intermediates for linezolid and related compounds
JP2008514702A (ja) 2004-09-29 2008-05-08 エーエムアール テクノロジー インコーポレイテッド 新規シクロスポリン類似体およびそれらの薬学的使用
EP2392328A1 (en) * 2005-05-09 2011-12-07 Hydra Biosciences, Inc. Compounds for modulating TRPV3 Function
TW200716636A (en) 2005-05-31 2007-05-01 Speedel Experimenta Ag Heterocyclic spiro-compounds
US7514068B2 (en) 2005-09-14 2009-04-07 Concert Pharmaceuticals Inc. Biphenyl-pyrazolecarboxamide compounds
WO2007056124A2 (en) 2005-11-04 2007-05-18 Hydra Biosciences, Inc. Compounds for modulating trpv3 function
NL2000351C2 (nl) * 2005-12-22 2007-09-11 Pfizer Prod Inc Estrogeen-modulatoren.
US8796267B2 (en) 2006-10-23 2014-08-05 Concert Pharmaceuticals, Inc. Oxazolidinone derivatives and methods of use
KR101222412B1 (ko) 2007-02-15 2013-01-15 에프. 호프만-라 로슈 아게 Ｔａａｒ1 리간드로서의 2-아미노옥사졸린
KR20100012031A (ko) 2007-04-19 2010-02-04 콘서트 파마슈티컬즈, 인크. 중수소화된 모르폴리닐 화합물
US7531685B2 (en) 2007-06-01 2009-05-12 Protia, Llc Deuterium-enriched oxybutynin
US20090131485A1 (en) 2007-09-10 2009-05-21 Concert Pharmaceuticals, Inc. Deuterated pirfenidone
US20090118238A1 (en) 2007-09-17 2009-05-07 Protia, Llc Deuterium-enriched alendronate
US20090088416A1 (en) 2007-09-26 2009-04-02 Protia, Llc Deuterium-enriched lapaquistat
US20090082471A1 (en) 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched fingolimod
US8119658B2 (en) 2007-10-01 2012-02-21 Bristol-Myers Squibb Company Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors
WO2009045476A1 (en) 2007-10-02 2009-04-09 Concert Pharmaceuticals, Inc. Pyrimidinedione derivatives
US20090105338A1 (en) 2007-10-18 2009-04-23 Protia, Llc Deuterium-enriched gabexate mesylate
WO2009051782A1 (en) 2007-10-18 2009-04-23 Concert Pharmaceuticals Inc. Deuterated etravirine
US20090131363A1 (en) 2007-10-26 2009-05-21 Harbeson Scott L Deuterated darunavir
AU2009226868A1 (en) * 2008-03-20 2009-09-24 F. Hoffmann-La Roche Ag Pyrrolidinyl derivatives and uses thereof
CA2728405A1 (en) * 2008-06-17 2010-01-14 Glenmark Pharmaceuticals, S.A. Chromane derivatives as trpv3 modulators
US8318928B2 (en) * 2008-12-15 2012-11-27 Glenmark Pharmaceuticals, S.A. Fused imidazole carboxamides as TRPV3 modulators
US8835461B2 (en) * 2009-03-26 2014-09-16 Shionogi & Co., Ltd. Substituted 3-hydroxy-4-pyridone derivative
MX2013000391A (es) * 2010-07-12 2013-03-08 Hoffmann La Roche 1-hidroxiimino-3-fenil-propanos.
WO2012019315A1 (en) 2010-08-10 2012-02-16 Abbott Laboratories Novel trpv3 modulators
MX2014004979A (es) 2011-10-24 2014-10-24 Abbvie Inc Derivados de metanol como moduladores de trpv3.

Also Published As

Publication number Publication date
SG187811A1 (en) 2013-03-28
BR112013003121A2 (pt) 2016-06-28
JP2013538800A (ja) 2013-10-17
CA2807538A1 (en) 2012-02-16
US20130150409A1 (en) 2013-06-13
EP2603490A1 (en) 2013-06-19
PH12013500275A1 (en) 2017-08-23
AU2010359001A1 (en) 2013-03-14
RU2013110324A (ru) 2014-09-20
EP2603490A4 (en) 2014-01-01
WO2012019315A1 (en) 2012-02-16
MX2013001612A (es) 2013-07-05
US9156788B2 (en) 2015-10-13
CN103140476A (zh) 2013-06-05
KR20130097748A (ko) 2013-09-03

Similar Documents

Publication Publication Date Title
CR20130106A (es) Nuevos moduladores de trpv3
UY34352A (es) 3-pirimidin-4-il-oxazolidin-2-onas como inhibidores de la idh mutante
CL2012003385A1 (es) Tratamiento para la incontinencia.
TR201813877T4 (tr) Spi̇nal müsküler atrofi̇ni̇n tedavi̇ edi̇lmesi̇ne yöneli̇k bi̇leşi̇kler.
ECSP099502A (es) 4-fenil-piran-3,5-dionas, 4-fenil-tiopiran-3,5-dionas y ciclohexantrionas como nuevos herbicidas
ECSP088961A (es) Nuevos herbicidas
CR20140161A (es) Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas
CO7101245A2 (es) Compuestos de benzaldehído sustituidos y métodos para su uso en incrementar la oxigenación del tejido
GT201400034A (es) Compuestos y composiciones como inhibidores de la quinasa c-kit
DOP2014000033A (es) Aminoquinazolinas como inhibidores de quinasa
UY33353A (es) Compuestos adecuados para el tratamiento de trastornos metabolicos y metodos de preparacion
UY33735A (es) Compuestos antivirales
CR20150217A (es) Inhibidores de histona demetilasas
PH12014502697A1 (en) New diazaspirocycloalkane and azaspirocycloalkane
UY34300A (es) COMPUESTOS Y COMPOSICIONES COMO INHIBIDORES DE LA QUINASA c-Kit
UY34467A (es) Procedimiento para la preparación de 5-fluoro-1h-pirazolopiridinas sustituidas
UY33943A (es) Derivados espirocíclicos de isoxazolina como agentes antiparasitarios.
CO6690755A2 (es) Heteroarilos como inhibidores de p13k
CR20130138A (es) Proceso para la preparación de inhibidores de pan-cdk de la fórmula (i), e intermediarios de la preparación
UY34216A (es) Nuevos compuestos que inhiben la actividad de la Lp-PLA2
CO6721048A2 (es) Anticuerpos que se unen a notum pectinacetilesterasa
UY34725A (es) Nuevos derivados de tienopirimidina, procesos para su preparación y sus usos terapéuticos.
ECSP11011245A (es) Novedosos herbicidas
MX2015003701A (es) Composiciones para tratamiento.
EP2731429A4 (en) COMPOUNDS, METHOD OF MANUFACTURING THEREFOR AND USE METHOD THEREFOR